Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.14
AMRI's Cash to Debt is ranked lower than
94% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. AMRI: 0.14 )
Ranked among companies with meaningful Cash to Debt only.
AMRI' s 10-Year Cash to Debt Range
Min: 0.14  Med: 5.31 Max: No Debt
Current: 0.14
Equity to Asset 0.42
AMRI's Equity to Asset is ranked lower than
76% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AMRI: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
AMRI' s 10-Year Equity to Asset Range
Min: 0.42  Med: 0.83 Max: 0.96
Current: 0.42
0.42
0.96
Interest Coverage 0.52
AMRI's Interest Coverage is ranked lower than
99% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMRI: 0.52 )
Ranked among companies with meaningful Interest Coverage only.
AMRI' s 10-Year Interest Coverage Range
Min: 0.52  Med: 22.78 Max: 1157.93
Current: 0.52
0.52
1157.93
F-Score: 2
Z-Score: 2.22
M-Score: -2.04
WACC vs ROIC
9.37%
65.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -0.17
AMRI's Operating margin (%) is ranked higher than
69% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. AMRI: -0.17 )
Ranked among companies with meaningful Operating margin (%) only.
AMRI' s 10-Year Operating margin (%) Range
Min: -36.35  Med: 3.64 Max: 46.92
Current: -0.17
-36.35
46.92
Net-margin (%) -3.01
AMRI's Net-margin (%) is ranked higher than
65% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. AMRI: -3.01 )
Ranked among companies with meaningful Net-margin (%) only.
AMRI' s 10-Year Net-margin (%) Range
Min: -31.74  Med: 4.77 Max: 77.21
Current: -3.01
-31.74
77.21
ROE (%) -3.64
AMRI's ROE (%) is ranked higher than
69% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. AMRI: -3.64 )
Ranked among companies with meaningful ROE (%) only.
AMRI' s 10-Year ROE (%) Range
Min: -22.52  Med: 4.01 Max: 29.93
Current: -3.64
-22.52
29.93
ROA (%) -1.70
AMRI's ROA (%) is ranked higher than
72% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. AMRI: -1.70 )
Ranked among companies with meaningful ROA (%) only.
AMRI' s 10-Year ROA (%) Range
Min: -17.99  Med: 2.83 Max: 23.57
Current: -1.7
-17.99
23.57
ROC (Joel Greenblatt) (%) 2.58
AMRI's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. AMRI: 2.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMRI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -35.54  Med: 9.22 Max: 174.12
Current: 2.58
-35.54
174.12
Revenue Growth (3Y)(%) 8.20
AMRI's Revenue Growth (3Y)(%) is ranked higher than
61% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. AMRI: 8.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMRI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5  Med: 7.75 Max: 78.2
Current: 8.2
-1.5
78.2
EPS Growth (3Y)(%) -54.80
AMRI's EPS Growth (3Y)(%) is ranked lower than
95% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. AMRI: -54.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMRI' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.1  Med: -8.20 Max: 37.3
Current: -54.8
-58.1
37.3
» AMRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AMRI Guru Trades in Q2 2014

Murray Stahl 56,000 sh (unchged)
George Soros Sold Out
Chuck Royce 1,315,610 sh (-2.16%)
Jim Simons 579,842 sh (-16.77%)
Joel Greenblatt 102,934 sh (-47.95%)
» More
Q3 2014

AMRI Guru Trades in Q3 2014

Paul Tudor Jones 16,255 sh (New)
Murray Stahl 56,000 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce 1,142,670 sh (-13.15%)
Jim Simons 209,242 sh (-63.91%)
» More
Q4 2014

AMRI Guru Trades in Q4 2014

Paul Tudor Jones 24,200 sh (+48.88%)
Chuck Royce 1,236,016 sh (+8.17%)
Murray Stahl 56,000 sh (unchged)
Jim Simons 126,142 sh (-39.71%)
» More
Q1 2015

AMRI Guru Trades in Q1 2015

Steven Cohen 233,100 sh (New)
Chuck Royce 1,291,216 sh (+4.47%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones 14,900 sh (-38.43%)
Jim Simons 62,242 sh (-50.66%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 25.19
AMRI's Forward P/E is ranked lower than
53% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 23.87 vs. AMRI: 25.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.73
AMRI's P/B is ranked higher than
71% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. AMRI: 2.73 )
Ranked among companies with meaningful P/B only.
AMRI' s 10-Year P/B Range
Min: 0.28  Med: 1.09 Max: 3.08
Current: 2.73
0.28
3.08
P/S 2.15
AMRI's P/S is ranked higher than
86% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. AMRI: 2.15 )
Ranked among companies with meaningful P/S only.
AMRI' s 10-Year P/S Range
Min: 0.31  Med: 1.69 Max: 2.93
Current: 2.15
0.31
2.93
POCF 45.27
AMRI's POCF is ranked lower than
58% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 34.67 vs. AMRI: 45.27 )
Ranked among companies with meaningful POCF only.
AMRI' s 10-Year POCF Range
Min: 4.9  Med: 12.40 Max: 283.33
Current: 45.27
4.9
283.33
Current Ratio 3.53
AMRI's Current Ratio is ranked lower than
57% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. AMRI: 3.53 )
Ranked among companies with meaningful Current Ratio only.
AMRI' s 10-Year Current Ratio Range
Min: 2.45  Med: 5.61 Max: 17.83
Current: 3.53
2.45
17.83
Quick Ratio 2.53
AMRI's Quick Ratio is ranked lower than
64% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. AMRI: 2.53 )
Ranked among companies with meaningful Quick Ratio only.
AMRI' s 10-Year Quick Ratio Range
Min: 1.84  Med: 4.89 Max: 17.25
Current: 2.53
1.84
17.25
Days Inventory 77.28
AMRI's Days Inventory is ranked higher than
64% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 116.21 vs. AMRI: 77.28 )
Ranked among companies with meaningful Days Inventory only.
AMRI' s 10-Year Days Inventory Range
Min: 21.14  Med: 63.97 Max: 125.59
Current: 77.28
21.14
125.59
Days Sales Outstanding 95.72
AMRI's Days Sales Outstanding is ranked lower than
71% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. AMRI: 95.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRI' s 10-Year Days Sales Outstanding Range
Min: 30.71  Med: 53.59 Max: 169.08
Current: 95.72
30.71
169.08

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.05
AMRI's Price/Tangible Book is ranked lower than
52% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. AMRI: 6.05 )
Ranked among companies with meaningful Price/Tangible Book only.
AMRI' s 10-Year Price/Tangible Book Range
Min: 0.39  Med: 1.60 Max: 16.72
Current: 6.05
0.39
16.72
Price/Projected FCF 3.74
AMRI's Price/Projected FCF is ranked higher than
55% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. AMRI: 3.74 )
Ranked among companies with meaningful Price/Projected FCF only.
AMRI' s 10-Year Price/Projected FCF Range
Min: 0.4  Med: 0.84 Max: 3.3
Current: 3.74
0.4
3.3
Price/Median PS Value 1.28
AMRI's Price/Median PS Value is ranked lower than
56% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. AMRI: 1.28 )
Ranked among companies with meaningful Price/Median PS Value only.
AMRI' s 10-Year Price/Median PS Value Range
Min: 0.23  Med: 1.23 Max: 25.2
Current: 1.28
0.23
25.2
Forward Rate of Return (Yacktman) (%) 16.21
AMRI's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 14.58 vs. AMRI: 16.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMRI' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -17.6  Med: 0.20 Max: 23.6
Current: 16.21
-17.6
23.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AYM.Germany,
Albany Molecular Research Inc is a Delaware corporation incorporated on June 20, 1991. It is a contract research and manufacturing organization providing customers integrated drug discovery, development and manufacturing services. The Company provides services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of Active Pharmaceutical Ingredients (API) and drug product for existing and experimental new drugs, as well as research, development and manufacturing for the agrochemical and other industries. With locations in the United States, Europe, and Asia, it maintains geographic proximity and flexible cost models. The Company has organized its activities into two distinct segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small-Scale Manufacturing (DDS). Its LSM activities include pilot- to commercial-scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing. Its remaining activities, including drug lead discovery, in vitro biology and DMPK, lead optimization, drug development, and small-scale commercial manufacturing, represent its DDS business segment. Its Drug Discovery Services includes assay development and design, screening, natural product services, custom synthesis and library synthesis, medicinal chemistry, bioanalytical services, among others. Its customers include pharmaceutical companies and biotechnology companies, as well as government research entities and non-profit organizations, which are a growing segment of its customer base. It also sells to a more limited extent, to companies who are in the businesses of agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics. The Company competes with contract research companies, contract drug manufacturing companies, research and academic institutions and with the internal research departments of biotechnology companies. The manufacture, transportation and storage of its products are subject to certain international, Federal, state and local laws and regulations.
» More Articles for AMRI

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011 
View on AMRI Jun 27 2010 
AMRI Announces Second Quarter 2009 Results Aug 04 2009 
AMRI Announces Fourth Quarter 2008 Results Feb 09 2009 
AMRI Names Senior Director, Analytical and Quality Services Jan 12 2009 

More From Other Websites
Edited Transcript of AMRI presentation 1-Jun-15 7:30pm GMT Jun 25 2015
AMRI continues to build Buffalo partnerships Jun 19 2015
AMRI and PerkinElmer Announce Drug Discovery Collaboration as part of the Buffalo Medical Innovation... Jun 17 2015
AMRI and PerkinElmer Announce Drug Discovery Collaboration as part of the Buffalo Medical Innovation... Jun 17 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 05 2015
HarkerBio signs three-year deal with AMRI Jun 01 2015
AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. Jun 01 2015
AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. Jun 01 2015
AMRI to Present at Jefferies 2015 Healthcare Conference May 20 2015
AMRI to Present at Jefferies 2015 Healthcare Conference May 20 2015
ALBANY MOLECULAR RESEARCH INC Financials May 15 2015
10-Q for Albany Molecular Research, Inc. May 10 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 10-Q, Quarterly Report May 08 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2015
Albany Molecular Research posts 1Q loss May 05 2015
Albany Molecular Research posts 1Q loss May 05 2015
AMRI Announces First Quarter 2015 Results May 05 2015
Q1 2015 Albany Molecular Research Inc Earnings Release - Before Market Open May 05 2015
10-K for Albany Molecular Research, Inc. May 04 2015
AMRI First Quarter Earnings May 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK